← Eichor
Study identifier: NCT06204835 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery

Condition: Hepatocellular Carcinoma  ·  Sponsor: Institute of Automation, Chinese Academy of Sciences

PhasePhase 1
Planned participants90
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

In this study, the investigators will detect hepatocellular carcinoma lesions using fluoescence imaging with ITGA6 targeting probes during tumor resection surgery. The aim is to evaluate wether intraoperative fluorescence imaging targeting ITGA6 can help to improve the detction effect of hepatocellular carcinoma, and finally help the accurate surgical resection. The main purposes of this study include: 1. To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the ITGA6 targeting probe. 2. To validate the safety and effectiveness of the proposed ITGA6 targeting probes for clinical application.

This description comes directly from the study's public registry record.

Talk to the study team

Xiaojing Shi, PhD  ·  13261798652  ·  shixiaojing2017@ia.ac.cn

Always discuss trial participation with your own doctor first.

Locations (2)

GuangdongGuangzhou, Guangdong, ChinaRecruiting
SichuanLuzhou, Sichuan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06204835